Metformin appeared to increase glucose uptake in lung cancer cells, according to results from a phase II trial.
Sequential afatinib and osimertinib improved median overall survival by almost 3.5 years in patients with EGFR T790M-positive non-small cell lung cancer, with an even greater benefit seen in those with Del19-positive disease.
NLR appeared to be a significant predictor of overall survival, and also showed a trend in favor of progression-free survival, among patients with stage III locally-advanced non-small cell lung cancer.
The neoantigens found in the patients’ tumors (non-small-cell lung cancer) which were highly dissimilar were enriched for hydrophobic sequences, and correlated with survival rates after the PD-1 checkpoint therapy.
Over that time, the number of active drugs in development has grown by more than 90%.
Treatment with 9-ING-41 significantly increased pancreatic tumor cell killing when combined with chemotherapy in pre-clinical trials.
Three scientists were awarded the Nobel Prize in Physiology of Medicine for their discovery of the mechanism of how cells regulate oxygen.
A study found an association between treatment with ibrutinib and an increased risk for death from toxicities.
Following administration of checkpoint inhibitor therapy, 2.6% of patients experienced an acute vascular event within 6 months of starting treatment.
The agency granted breakthrough therapy designation to niraparib for the treatment of men with BRCA1/2-mutant positive metastatic castration-resistant prostate cancer.